Catalent has completed its previously announced acquisition of Accucaps Industries Limited, an Ontario, Canada-based developer and manufacturer of over-the-counter (OTC), high potency, and conventional pharmaceutical softgels. The company announced the acquisition in November 2016.

The acquisition complements Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity, adding a portfolio of products supplied to pharmaceutical companies in North America, and two facilities offering integrated softgel development, manufacturing, and packaging. Financial details of the transaction were not disclosed.

Accucaps’ more than 500 employees at its two facilities in Windsor and Strathroy, Ontario, join Catalent’s global network of 11 softgel technologies facilities. Accucaps’ facilities house blistering, bottling, and other packaging capabilities as well as high-potency prescription softgel development and manufacturing expertise that complement Catalent’s capabilities.

Source: Catalent